RMC-0331（Cat No.:I044531）is a small-molecule investigational drug developed by Revolution Medicines as a selective inhibitor of mutant RAS-driven signaling pathways, specifically targeting oncogenic RAS variants implicated in human cancers. It is part of a broader class of RAS(ON) inhibitors designed to directly bind and inhibit RAS in its active, GTP-bound state—previously considered “undruggable.” RMC-0331 aims to disrupt downstream MAPK pathway signaling, thereby suppressing tumor cell proliferation and survival. It is currently in preclinical or early clinical evaluation for RAS-driven solid tumors, representing a promising precision oncology approach to targeted cancer therapy.